Citarinostat is an orally active, small-molecule Histone Deacetylase (HDAC) Inhibitor which is being combined here to further augment the immune activity of the vaccine. Citarinostat has not been approved by the FDA as a treatment for any disease.
| SparkCures ID | 207 |
|---|---|
| Developed By | Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb |
| Generic Name | Citarinostat |
| Additional Names | ACY-241, CC-96241 |
| Treatment Classifications |
There are no resources, links or videos to display for this treatment.